Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alector, Inc.

Market Cap 170M 147M 135M 127M 238M 16.15B 241M 1.6B 623M 7.86B 637M 624M 27.21B P/E Ratio 2026 *
-1.79x
P/E Ratio 2027 * -2.39x
Enterprise Value -77.27M -66.8M -61.53M -57.63M -108M -7.35B -110M -729M -283M -3.57B -290M -284M -12.38B EV / Sales 2026 *
-11.3x
EV / Sales 2027 * -6.84x
Free-Float
87.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-2.55%
1 week-15.47%
Current month-29.17%
1 month-25.37%
3 months-34.05%
6 months+4.79%
Current year-1.92%
1 week 1.48
Extreme 1.485
1.74
1 month 1.48
Extreme 1.485
2.37
Current year 1.48
Extreme 1.485
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
43.32
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 70 01/05/2013
Director of Finance/CFO 53 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
03/06Sell

Controller/Auditor

-3,475 0.0031%
02/06Sell

Chief Financial Officer

-19,360 0.0174%
02/06Sell

Founder

-87,216 0.0786%
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-15.47%-6.13%-78.98% 174M
+1.03%+7.52%+54.74%+114.98% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+1.12%+1.06%-14.15%-17.13% 22.64B
+1.17%-6.74%-0.13%+394.19% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+2.24%+9.06%-39.50% 15.3B
-0.69%+1.22%+28.24%+176.72% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +1.25%-1.10%+25.34%+86.71% 21.01B
Weighted average by Cap. +1.58%+1.59%+33.60%+100.61%

Financials

2026 *2027 *
Net sales 6.86M 5.93M 5.46M 5.11M 9.59M 652M 9.74M 64.71M 25.14M 317M 25.73M 25.18M 1.1B 22.88M 19.78M 18.22M 17.07M 32M 2.18B 32.49M 216M 83.89M 1.06B 85.87M 84.04M 3.67B
Net income -94.11M -81.36M -74.95M -70.2M -132M -8.95B -134M -888M -345M -4.35B -353M -346M -15.08B -96.62M -83.53M -76.94M -72.07M -135M -9.19B -137M -912M -354M -4.47B -363M -355M -15.48B
Net Debt -247M -214M -197M -184M -346M -23.5B -351M -2.33B -906M -11.43B -927M -908M -39.59B -326M -282M -260M -243M -456M -31.04B -463M -3.08B -1.2B -15.1B -1.22B -1.2B -52.28B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
12/06/26 1.530 $ -2.55% 263,829
11/06/26 1.570 $ +3.29% 428,244
10/06/26 1.520 $ -6.75% 429,021
09/06/26 1.630 $ -0.61% 439,473
08/06/26 1.640 $ +0.31% 667,834
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.530USD
Average target price
3.100USD
Spread / Average Target
+102.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!